title: Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia
creator: Richter, Anna
creator: Roolf, Catrin
creator: Hamed, Mohamed
creator: Gladbach, Yvonne Saara
creator: Sender, Sina
creator: Konkolefski, Christoph
creator: Knübel, Gudrun
creator: Sekora, Anett
creator: Fuellen, Georg
creator: Vollmar, Brigitte
creator: Murua Escobar, Hugo
creator: Junghanss, Christian
subject: ddc-610
subject: 610 Medical sciences Medicine
description: Background: The tumor suppressor protein phosphatase and tensin homolog (PTEN) is a key regulator of the PI3K/AKT pathway which is frequently altered in a variety of tumors including a subset of acute B-lymphoblastic leukemias (B-ALL). While PTEN mutations and deletions are rare in B-ALL, promoter hypermethylation and posttranslational modifications are the main pathways of PTEN inactivation. Casein Kinase II (CK2) is often upregulated in B-ALL and phosphorylates both PTEN and DNA methyltransferase 3A, resulting in increased PI3K/AKT signaling and offering a potential mechanism for further regulation of tumor-related pathways.    Methods: Here, we evaluated the effects of CK2 inhibitor CX-4945 alone and in combination with hypomethylating agent decitabine on B-ALL proliferation and PI3K/AKT pathway activation. We further investigated if CX-4945 intensified decitabine-induced hypomethylation and identified aberrantly methylated biological processes after CK2 inhibition. In vivo tumor cell proliferation in cell line and patient derived xenografts was assessed by longitudinal full body bioluminescence imaging and peripheral blood flow cytometry of NSG mice.       Results: CX-4945 incubation resulted in CK2 inhibition and PI3K pathway downregulation thereby inducing apoptosis and anti-proliferative effects. CX-4945 further affected methylation patterns of tumor-related transcription factors and regulators of cellular metabolism. No overlap with decitabine-affected genes or processes was detected. Decitabine alone revealed only modest anti-proliferative effects on B-ALL cell lines, however, if combined with CX-4945 a synergistic inhibition was observed. In vivo assessment of CX-4945 in B-ALL cell line xenografts resulted in delayed proliferation of B-ALL cells. Combination with DEC further decelerated B-ALL expansion significantly and decreased infiltration in bone marrow and spleen. Effects in patient-derived xenografts all harboring a t(4;11) translocation were heterogeneous.    Conclusions: We herein demonstrate the anti-leukemic potential of CX-4945 in synergy with decitabine in vitro as well as in vivo identifying CK2 as a potentially targetable kinase in B-ALL.
publisher: BioMed Central ; Springer
date: 2019
type: Article
type: info:eu-repo/semantics/article
type: NonPeerReviewed
format: application/pdf
identifier: https://archiv.ub.uni-heidelberg.de/volltextserverhttps://archiv.ub.uni-heidelberg.de/volltextserver/26158/1/12885_2019_Article_5411.pdf
identifier: DOI:
identifier: urn:nbn:de:bsz:16-heidok-261583
identifier:   Richter, Anna ; Roolf, Catrin ; Hamed, Mohamed ; Gladbach, Yvonne Saara ; Sender, Sina ; Konkolefski, Christoph ; Knübel, Gudrun ; Sekora, Anett ; Fuellen, Georg ; Vollmar, Brigitte ; Murua Escobar, Hugo ; Junghanss, Christian  (2019) Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.  BMC Cancer, 19 (202).  pp. 1-11.  ISSN 1471-2407     
relation: https://archiv.ub.uni-heidelberg.de/volltextserver/26158/
rights: info:eu-repo/semantics/openAccess
rights: Please see front page of the work (Sorry, Dublin Core plugin does not recognise license id)
language: eng